Eco Animal Health Group PLC EUROPEAN MARKETING AUTHORISATION FOR AIVLOSIN(R) (2948R)

TIDMEAH

RNS Number : 2948R

Eco Animal Health Group PLC

29 June 2020

ECO Animal Health Group plc

("ECO" or the "Group")

(AIM: EAH)

EUROPEAN MARKETING AUTHORISATION FOR AIVLOSIN(R) IN PIGS

ECO Animal Health Group plc (the "Group") is pleased to announce that, as anticipated, a marketing authorisation has been received from the European Medicines Agency (EMA) for the use of Aivlosin(R) 625 mg/g Water Soluble Granules (WSG) for the treatment and metaphylaxis (disease control) of Mycoplasma hyopneumoniae in pigs.

The Group had previously announced a positive opinion on 22(nd) May 2020 with the marketing authorisation expected within two months.

Mycoplasma hyopneumoniae is the most common primary pathogen in pig respiratory disease and is a key instigator of secondary bacterial and viral pathogens. The EU market accounts for approximately 15 per cent of the world's swine market.

Aivlosin(R), ECO's patented antimicrobial, is used under veterinary prescription for the treatment of a variety of economically important respiratory and enteric (gut) diseases in poultry and pigs.

Marc Loomes, CEO, commented: "We are very pleased that this marketing authorisation has been received after only one month and we look forward to offering Aivlosin(R) for the treatment of Mycoplasma infections in this important market. This further approval underlines the value of Aivlosin(R) for the safe and highly effective treatment of a range of diseases and infections."

Contacts:

 
ECO Animal Health Group plc 
 Marc Loomes (CEO) 
 Christopher Wilks (CFO)                020 8447 8899 
IFC Advisory 
 Graham Herring 
 Zach Cohen                             020 3934 6630 
N+1 Singer (Nominated Adviser & Joint 
 Broker) 
 Mark Taylor 
 Peter Steel 
 Alex Bond                              020 7496 3000 
Peel Hunt LLP (Joint Broker) 
 James Steel 
 Dr Christopher Golden                  020 7418 8900 
 

ECO Animal Health Group plc ("ECO" or "the "GROUP") researches, develops and commercialises products for livestock. Our business strategy is to generate shareholder value by achieving the maximum sales potential from the existing product portfolio whilst investing in Research and Development ("R&D") for new products, particularly vaccines, and seeking to in-license new products.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

MSCBIGDLDUDDGGI

(END) Dow Jones Newswires

June 29, 2020 02:00 ET (06:00 GMT)